Skip to main content

Table 1 Demographic information for the PWS and AS groups

From: Exploring autism symptoms in an Australian cohort of patients with Prader-Willi and Angelman syndromes

 

PWS

AS

Medication use

 Growth hormone

68.0%

0%

 Anticonvulsant

8.0%

73.7%

Genetic subtype

 Deletion

24.0%

47.4%

 UPD

64.0%

15.8%

 Imprinting centre defect

8.0%

0%

 Abnormal methylationa

4.0%

5.2%

UBE3A mutation

NA

31.6%

  1. aMethylation analysis confirmed PWS or AS diagnosis, but further analysis to confirm specific subtypes had not been undertaken